Bosh sahifaICPT • BMV
add
Intercept Pharmaceuticals Ord Shs
Yopilish kursi
329,00 $
Yillik diapazon
329,00 $ - 329,00 $
Bozor kapitalizatsiyasi
794,36 mln USD
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2023info | Y/Y qiyosi |
|---|---|---|
Daromad | 88,79 mln | 14,44% |
Joriy xarajat | 86,95 mln | -0,41% |
Sof foyda | -2,79 mln | -101,04% |
Sof foyda marjasi | -3,14 | -100,91% |
Har bir ulushga tushum | 0,08 | -99,20% |
EBITDA | 1,74 mln | 117,27% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2023info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 322,71 mln | -34,25% |
Jami aktivlari | 393,16 mln | -29,72% |
Jami passivlari | 321,32 mln | -28,87% |
Umumiy kapital | 71,84 mln | — |
Tarqatilgan aksiyalar | 41,83 mln | — |
Narxi/balansdagi bahosi | 191,28 | — |
Aktivlardan daromad | 0,93% | — |
Kapitaldan daromad | 1,18% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2023info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -2,79 mln | -101,04% |
Operatsiyalardan naqd pul | 16,69 mln | 200,59% |
Sarmoyadan naqd pul | 59,77 mln | -81,97% |
Moliyadan naqd pul | -110,00 mln | 57,27% |
Naqd pulning sof oʻzgarishi | -33,70 mln | -163,39% |
Boʻsh pul | 16,70 mln | 211,23% |
Haqida
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
CEO
Tashkil etilgan
2002
Xodimlar soni
341
